ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

BOC Sciences Releases High-Standard GalNAc-siRNA Conjugation Services to Support siRNA Drug Delivery to Liver

By: Get News

New York, USA - December 29, 2022 - BOC Sciences today announced the release of premium GalNAc-siRNA conjugation services to further support the delivery of siRNA drugs to the liver.

N-Acetylgalactosamine (GalNAc) is an amino sugar derivative of galactose and can be used as a targeting ligand in antisense oligonucleotides (ASO) and siRNA therapeutics. Meanwhile, the asialoglycoprotein receptor (ASGR) is an ideal hepatocyte-specific candidate for targeted drug delivery due to its high capacity for substrate clearance from serum via receptor-mediated endocytosis and high hepatocyte expression that conserved across species. Mechanistically, GalNAc binds to the ASGR receptor to activate receptor-mediated endocytosis rapidly. So, conjugation of GalNAc has become a major strategy for the delivery of oligos to hepatocytes.

As a comprehensive manufacturer of chemicals in the preclinical stage, BOC Sciences leverages its wide spectrum of business in the fields of development, manufacturing, marketing, and distribution to help researchers make best-informed decisions tailored to their evolving needs for premium chemicals. To enhance the delivery capability of siRNA candidate drugs to target cells, BOC Sciences' expert team can design and synthesize siRNAs based on targeting receptors while combining GalNAc molecules to form GalNAc-siRNA conjugates. Not to mention the GalNAc-siRNA targeting strategy has become a relatively simple solution for siRNA drug delivery to the liver and has shown improved tissue-specific delivery and efficacy in ASO and siRNA areas.

Meanwhile, BOC Sciences provides one-stop fermentation services to manufacture oligonucleotides and nucleic acids (such as plasmid DNA). Its scientific team can personalize fermentation process solutions according to the target product requirements and requested fermentation scales. After years of development, the company has established large-scale fermentation tanks of different volumes, ranging from 4,000 L to 12,000 L, with a total of over 100,000 L capability, all to meet the different needs of researchers for their scientific projects.

"Utilizing the power of RNAi molecules, we have developed different GalNAc-siRNA conjugates for efficient drug delivery to targeting receptors, including hard-to-transfect cells. Based on our well-established scale-up fermentation platform, our experts can provide international clients with high-standard siRNA products through comprehensive fermentation strategies. We are confident in providing high-quality service to facilitate our clients' GalNAc-siRNA therapeutics development." The marketing manager at BOC Sciences said.

About BOC Sciences

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. The company has been supplying high-quality products for its esteemed customers in academia, pharmaceuticals, biotech, CDMO, material sciences, and agriculture to support research and production needs. In addition, the company works closely with synthetic laboratories, fermentation labs, OMs, and global partners and proudly offers a full range of product portfolios.

Media Contact
Company Name: BOC Sciences
Contact Person: Alex Brown
Email: Send Email
Phone: 1-631-485-4226
Country: United States
Website: https://www.bocsci.com



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.